These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19363132)

  • 21. What is Wrong With Cardiac Conditioning? We May be Shooting at Moving Targets.
    Iliodromitis EK; Cohen MV; Dagres N; Andreadou I; Kremastinos DT; Downey JM
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):357-69. PubMed ID: 25627214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preconditioning and postconditioning: underlying mechanisms and clinical application.
    Hausenloy DJ; Yellon DM
    Atherosclerosis; 2009 Jun; 204(2):334-41. PubMed ID: 19081095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Past and present course of cardioprotection against ischemia-reperfusion injury.
    Liem DA; Honda HM; Zhang J; Woo D; Ping P
    J Appl Physiol (1985); 2007 Dec; 103(6):2129-36. PubMed ID: 17673563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating the possible mechanisms involved in adenosine preconditioning-induced cardioprotection in rats.
    Singh L; Virdi JK; Maslov LN; Singh N; Jaggi AS
    Cardiovasc Ther; 2018 Jun; 36(3):e12328. PubMed ID: 29604187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age, cell signalling and cardioprotection.
    Taylor RP; Starnes JW
    Acta Physiol Scand; 2003 Jun; 178(2):107-16. PubMed ID: 12780384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardioprotective-mimetics reduce myocardial infarct size in animals resistant to ischemic preconditioning.
    Gumina RJ; El Schultz J; Moore J; Beier N; Schelling P; Gross GJ
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):315-22. PubMed ID: 16382293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.
    Heusch G; Gersh BJ
    Eur Heart J; 2017 Mar; 38(11):774-784. PubMed ID: 27354052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological pre- and post- conditioning agents: reperfusion-injury of the heart revisited.
    Andreadou I; Iliodromitis EK; Koufaki M; Kremastinos DT
    Mini Rev Med Chem; 2008 Aug; 8(9):952-9. PubMed ID: 18691153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts.
    Kocsis GF; Pipis J; Fekete V; Kovács-Simon A; Odendaal L; Molnár E; Giricz Z; Janáky T; van Rooyen J; Csont T; Ferdinandy P
    Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2406-9. PubMed ID: 18359895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat.
    Sivarajah A; McDonald MC; Thiemermann C
    Shock; 2006 Aug; 26(2):154-61. PubMed ID: 16878023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different preconditioning stimuli invoke disparate electromechanical and energetic responses to global ischemia in rat hearts.
    Rehring TF; Bender PR; Cairns CB; Joo K; Friese RS; Shapiro JI; Cleveland JC; Banerjee A
    Can J Physiol Pharmacol; 1997 Apr; 75(4):335-42. PubMed ID: 9196860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical translation of cardioprotective strategies : report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection.
    Hausenloy DJ; Yellon DM
    Basic Res Cardiol; 2008 Sep; 103(5):493-500. PubMed ID: 18600363
    [No Abstract]   [Full Text] [Related]  

  • 33. Ischemic conditioning: the challenge of protecting the diabetic heart.
    Wider J; Przyklenk K
    Cardiovasc Diagn Ther; 2014 Oct; 4(5):383-96. PubMed ID: 25414825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection in the aged heart: preventing the heart-break of old age?
    Juhaszova M; Rabuel C; Zorov DB; Lakatta EG; Sollott SJ
    Cardiovasc Res; 2005 May; 66(2):233-44. PubMed ID: 15820192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocotrienols in cardioprotection.
    Das S; Nesaretnam K; Das DK
    Vitam Horm; 2007; 76():419-33. PubMed ID: 17628184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.
    Hausenloy DJ; Tsang A; Yellon DM
    Trends Cardiovasc Med; 2005 Feb; 15(2):69-75. PubMed ID: 15885573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is oxytocin a therapeutic factor for ischemic heart disease?
    Alizadeh AM; Mirzabeglo P
    Peptides; 2013 Jul; 45():66-72. PubMed ID: 23659864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 5 different remifentanil strategies against myocardial ischemia-reperfusion injury.
    Chun KJ; Park YH; Kim JS; Jang Y; Kim JH; Kim J; Lee MY
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):926-30. PubMed ID: 21514843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions.
    Vinten-Johansen J; Shi W
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):260-6. PubMed ID: 21821526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial protection by pre- and post-anesthetic conditioning.
    Pasqualin RC; Auler JO
    Rev Bras Anestesiol; 2008; 58(5):512-9, 506-12. PubMed ID: 19382410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.